And they're off... Melanoma March 2016 begins!
29 February 2016
Melanoma March 2016 has kicked off with a bang! More than 300 people marched in Rockingham, WA and Devonport, TAS this weekend. It was great to see the melanoma community uniting to remember those who they have lost to melanoma, support those fighting the disease, and to raise money to support melanoma research.
Clinton Heal from MelanomaWA said of the Rockingham march “There were also many people there living with melanoma, and their family and friends were there to get behind them and the balloon release ceremony was a great way to both remember and rally together for all those touched by melanoma. With a large increase in participation compared to the 2015 event, we are excited for even bigger and better things for the 2017 Rockingham Melanoma March!”.
MIA’s Merrin Lavender attended the Devonport Melanoma March, which was the first march ever held in Tasmania. She said it was a great success and guest speakers include the founder of Melanoma TAS and the Deputy Premier of Tasmania, Jeremy Rockliff.
Thank you to everyone who came out to support Melanoma March and to our dedicated volunteers who have been tirelessly organsing these events.
This weekend marks just the beginning of a 6-week campaign for Melanoma March where Australia will unite against melanoma in 24 locations around the country. Register or make a donation to support Melanoma March today.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.